Technology-driven interactive care management identifies and resolves more clinical issues than a claims-based alerting system

Disease Management

Volumn 8, Issue 3, 2005, Pages 188-197

  Juster, Iver A ^a  

^a ActiveHealth Management   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DOCTOR PATIENT RELATION; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH PROGRAM; HOSPITAL CARE; HOSPITAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT CARE; PRACTICE GUIDELINE; TECHNOLOGY;

DECISION SUPPORT SYSTEMS, CLINICAL; DISEASE MANAGEMENT; HUMANS; INSURANCE CLAIM REPORTING; INTERDISCIPLINARY COMMUNICATION; MANAGED CARE PROGRAMS; NURSE'S ROLE; PATIENT PARTICIPATION; PHYSICIAN'S ROLE;

EID: 21744433346     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2005.8.188     Document Type: Article

References (40)

1. Brophy JM. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001;134: 550-560.
2. Avezum A. Beta-blocker therapy for congestive heart failure: a systematic overview and critical appraisal of the published trials. Can J Cardiol 1998;14:1045-1053.
3. Packer M. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol HF Study Group. N Engl J Med 1996;334: 1349-1355.
4. U.S. Carvedilol HF Study Group. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization, and costs. J Am Coll Cardiol 2001;37:1692-1699.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
6. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL randomized intervention trial in congestive heart failure. JAMA 2000;283:1295-1302.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure I asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
9. Cook DJ, Guyatt GH. Interpreting, integrating, and individualizing evidence about the prevention of diabetic nephropathy. Ann Intern Med 1999;131: 707-708.
10. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-1133.
11. Kshirsagar AV. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000;35:695-707.
12. The Heart Outcomes Prevention Evaluation Trial Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
13. Clarke JL, Nash DB. The effectiveness of heart failure disease management: Initial findings from a comprehensive program. Dis Manage 2002;5:215-223.
14. Saadine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Venkat Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:565-574.
15. Assurance NCfQ. Health Plan Employer and Data Information Set (HEDIS) Commercial HEDIS 2003 audit means, percentiles and ratios. Available: 〈www.ncqa.org/Programs/HEDIS/Audit/HEDIS_ 2003_Audit_Means_Ratios. htm〉, 2004.
16. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA 1999;281:1830-1835.
17. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
18. Beta-blocker Heart Attack Study Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247: 1707-1714.
19. Kostis JB, Lacy CR. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J 1997;133:550-557.
20. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635-2645.
21. Cain M, Mittman R. Diffusion of innovation in health care. Institute for the Future (prepared for the California HealthCare Foundation), 2002.
22. Oxman DA, Thompson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Can Med Assoc J 1995;153:1423-1431.
23. Cockburn J. Adoption of evidence into practice: can change be sustainable? Med J Aust 2004;180:S66-S67.
24. Bodenheimer T. Interventions to improve chronic illness care: evaluating their effectiveness. Dis Manage 2003;6:63-71.
25. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med 1993;329:1271-1273.
26. Hunt DL, Haynes RB, Hanna SE, Smith K. Effects of computer-based clinical decision support systems on physician performance and patient outcomes. JAMA 1998;280:1339-1346.
27. Schneider EC, Eisenberg JM. Strategies and methods for aligning current and best medical practices: the role of information technologies. West J Med 1998;168:311-318.
28. Anari M, Shlipak MG, Heidenreich PA, et al. Improving guideline adherence: a randomized trial evaluating strategies to increase β-blocker use in heart failure. Circulation 2003;107:2799-2804.
29. Javitt JC, Steinberg G, Locke T, Couch JB, Jacques J, Juster IA, and Reisman L. Using a claims data-based sentinel system to improve compliance with clinical guidelines: Results of a randomized prospective study. Am J Manag Care 2005;11:93-102.
30. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:55-61.
31. Koelling TM, Eagle KA. Editorial comment: measuring quality of outpatient cardiovascular care. J Am Coll Cardiol 2003;41:69-72.
32. Davis DA, Thompson MA, Oxman DA, Haynes RB. Evidence for the effectiveness of CME: a review of 50 randomized controlled trials. JAMA 1992;268:1111-1117.
33. Fritsche L, Greenhalgh T, FalckYtter Y, Neumayer H-H, Kunz R. Do short courses in evidence based medicine improve knowledge and skills? Validation of Berlin questionnaire and before and after study of courses in evidence-based medicine. BMJ 2002;325: 1338-1341.
34. Shekelle PG, Oritz E, Rhodes S. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines. JAMA 2001;286:1461-1467.
35. Gibson PG, Coughlan J, Wilson AJ. Self-management education and regular practitioner review for adults with asthma. Cochrane Library 2001; January.
36. Lorig KR, Ritter P, Stewart AL. Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care 2001;39:1217-1223.
37. Aubert RE. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization: a randomized, controlled trial. Ann Intern Med 1998;129:605-612.
38. Siderov J, Gabbay R, Harris R, et al. Disease management for diabetes mellitus: impact on hemoglobin A1c. Am J Manage Care 2000;6:1217-1226.
39. Villagra VG, Ahmed T. Effectiveness of a disease management program for patients with diabetes. Health Aff (Millwood) 2004;21:255-266.
40. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events. Ann Intern Med 2002;136:157-160.